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Abstract
Background: Lysozyme, one of the major protein components of human milk that is also synthesized
by a significant percentage of breast carcinomas, is associated with lesions that have a favorable
outcome in female breast cancer. Here we evaluate the expression and prognostic value of lysozyme
in male breast cancer (MBC).
Methods: Lysozyme expression was examined by immunohistochemical methods in a series of 60
MBC tissue sections and in 15 patients with gynecomastia. Staining was quantified using the
HSCORE (histological score) system, which considers both the intensity and the percentage of cells
staining at each intensity. Prognostic value of lysozyme was retrospectively evaluated by multivariate
analysis taking into account conventional prognostic factors.
Results: Lysozyme immunostaining was negative in all cases of gynecomastia. A total of 27 of 60
MBC sections (45%) stained positively for this protein, but there were clear differences among them
with regard to the intensity and percentage of stained cells. Statistical analysis showed that lysozyme
HSCORE values in relation to age, tumor size, nodal status, histological grade, estrogen receptor
status, metastasis and histological type did not increase the statistical significance. Univariate
analysis confirmed that both nodal involvement and lysozyme values were significant predictors of
short-term relapse-free survival. Multivariate analysis, according to Cox`s regression model, also
showed that nodal status and lysozyme levels were significant independent indicators of short-term
relapse-free survival.
Conclusion: Tumor expression of lysozyme is associated with lesions that have an unfavorable
outcome in male breast cancer. This milk protein may be a new prognostic factor in patients with
breast cancer.
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Introduction
Breast cancer is the most frequent malignant tumor in the
female population, and represents a leading cause of death
in women, with a rising incidence recently in western coun-
tries. These carcinomas display a long natural history, and
a high variability in biological and clinical behavior. Thus,
major efforts have been directed at finding new prognostic
factors and therapeutic methods, but breast-cancer-related
mortality seems to be stable over time [1–3]. On the other
hand, MBC is a very rare disease, with a male-to-female
ratio of only 1:99. The incidence pattern of MBC increases
logarithmically with age and differs from that seen in
women, which shows a decrease at the time of menopause
and then increases with age.
The natural history of both tumors is very similar, and histo-
logical features seem to be indistinguishable, but epidemi-
ology and hormonal status are very different. Because of
the rarity of the disease in men, controlled prospective clini-
cal trials are not feasible; it is unlikely, therefore, that we will
ever know as much about MBC as we do about its coun-
terpart in women. The hormonal milieu represents the main
difference between both tumors and it is difficult to under-
stand the development of two so histologically similar
tumors in such different hormonal environments [4–6].
Lysozyme, discovered by Fleming in 1922 [7], is one of
the major protein components of human milk, and has also
been detected as a component of the secretion fluid from
nonlactating women [8]. This muramidase plays an impor-
tant role in the primitive nonspecific defense mechanism
related to the monocytic-macrophagic system [9,10]. In
nonlactating women, Type I secretions (characterized by
containing Zn-α2-glycoprotein, apolipoprotein D and gross
cystic disease fluid protein-15) are found in most women
without breast pathology or with benign breast diseases.
Type II secretions contain high concentrations of lactofer-
rin, lysozyme, and alpha-lactalbumin [11]; this pattern is
found in the majority of women studied who have given
birth at some point in the previous four years and in a high
proportion of oral-contraceptive users. The Type II pattern
was also found in a significant percentage (47%) of breast
cancer patients, but only in 7% of healthy women after
excluding women who have given birth and OCP users
[12]. It is also remarkable that this Type II polypeptide
pattern is associated with a peak of prolactin secretion
after thyroxine-releasing hormone stimulation test in pre-
menopausal nonlactating women [13].
Very recent results from our group have demonstrated
positive immunostaining for lysozyme in 69.4% of a series
of 177 female breast cancers (FBCs), and it has been
associated with factors of favorable outcome such as
tumor size, nodal status, and histological grade [14].
Apolipoprotein D and pepsinogen C, two androgen-
induced proteins, are also expressed by a significant
percentage of male breast carcinomas [15,16]. Both pro-
teins have shown a significant association with factors of
favorable outcome in MBC and also a higher expression in
MBC when compared with FBC [17,18].
The aim of the present study was to evaluate the expres-
sion of lysozyme in MBC and to describe the behavior of




This study was performed on a group of 60 males diag-
nosed with invasive breast cancer between 1979 and
1995 and treated at 17 surgical departments in Spain
(listed in the Acknowledgements section). The mean age
of the patients was 59.3 years, with a range of 26 to
89 years. Histological grade of tumors was determined
according to criteria reported by Bloom and Richardson
[19], whereas nodal status was assessed histopathologi-
cally. Estrogen receptor content was measured in cytosol
extracts using a commercially available kit from Abbott
Laboratories (North Chicago, IL, USA). Breast cancers
were considered estrogen-receptor-positive if they con-
tained more than 10 fmol/mg total protein.
Surgery was the primary therapeutic method in all
patients. The extent of surgery differed according to the
surgeon and the institution. Thus, lumpectomy plus axillary
dissection was performed in four patients, total mastec-
tomy plus axillary dissection in six cases, modified radical
mastectomy in 44 patients, and radical mastectomy in 12
patients. Thirty-four patients received postoperative adju-
vant radiotherapy, 31 chemotherapy, and 39 Tamoxifen.
Mean follow-up period was 43.9 months, 38.5 months for
node-negative tumors, and 44.8 for node-positive carcino-
mas. During this follow-up period 11 patients developed
tumor recurrence, and four of them died of breast cancer.
Five patients died of causes unrelated to breast cancer.
We also analyzed the role of lysozyme in benign male
breast epithelium, by including in the present study speci-
mens from 15 patients treated for gynecomastia (mean
age 42; range 16–69 years).
Methods
Lysozyme purification and antiserum production
Lysozyme was purified from milk of lactating women
according to the high performance liquid chromatography
procedure. The purity of the obtained antigen was con-
firmed by automatic Edman degradation after treatment of
the protein with pyroglutamate aminopeptidase. Antiserum
against the purified protein was raised in New Zealand
white rabbits following the method described by
Vaitukaitis [20]. The immunized rabbits were bled 6 weeks
after protein injection and the obtained serum was
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dialyzed for 24 hours at 4°C against 20 mM phosphate
buffer, pH 7.2. Then, the dialyzed material was chrom-
atographed in a column of diethylaminoethyl cellulose
equilibrated and eluted in the same phosphate buffer.
Finally, the IgG-containing fractions were collected and
stored at –20°C until used.
Immunoblot analysis
Samples were analyzed by SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) in 13% gels according to the
method of Laemmli [21]. The proteins separated by SDS-
PAGE were electrophoretically transferred to a Hybond
ECL nitrocellulose membrane (Amersham Biosciences,
Uppsala, Sweden) at 100 V for 1 hour in a Bio-Rad Trans
Blot apparatus (Bio-Rad, Hercules, CA, USA) with a
buffer containing 10 mM 3-(cyclohexylamino)-1-propane-
sulfonic acid, 4 mM NaOH, and 20% (v/v) methanol. After
transfer, the filter was dried, blocked in phosphate-
buffered saline solution containing 0.1% Tween 20 and
5% dry powdered milk, and incubated with rabbit anti-
body against human lysozyme diluted 1/1000 in the same
buffer. After 1 hour, the filter was washed three times with
0.1% Tween 20 in phosphate-buffered saline, incubated
for 1 hour with peroxidase-labeled donkey antibodies
against rabbit immunoglobulins diluted 1/1000, and
washed as before. The immunoreactive bands were
detected with SuperSignal Chemiluminescent Substrate
(Pierce, Milwaukee, WI, USA).
Immunohistochemical staining
Immunohistochemical assays were performed on 6-µm-
thick, formalin-fixed, paraffin-embedded tissue sections
using the streptavidin-biotin supersensitive method (Bio-
genex, San Ramon, CA, USA). Incubation with antiserum
against lysozyme (diluted 1/200 in 20 mM phosphate
buffer, pH 7.2, and 1% bovine seroalbumin) was per-
formed at room temperature for 30 minutes. Then, slides
were incubated for 20 minutes with the second biotiny-
lated antibody obtained from Biogenex. Endogenous alka-
line phosphatase was blocked with levamisole (diluted
1/50). The reaction with streptavidin-alcalin phosphatase
complex reagent (Biogenex) was performed for
20 minutes at room temperature and the reaction was
developed with fast red in Tris-buffer, pH 7.2 with naphtol-
phosphate. Later, the slides were contrasted with Mayer
hematoxylin and mounted in Aquatex (Merck, Darmstadt,
Germany). Specificity of staining was determined using
controls that involved incubation of tissue sections with
buffer alone or with an equal amount of IgG from non-
immunized rabbits. In both cases, there was no significant
staining. Furthermore, immunostaining was completely
abolished by antiserum preincubation with lysozyme puri-
fied from maternal milk as described previously. Tissue
sections were scored in a semiquantitative fashion
according to the method described by McCarty et al. [22],
which considers both the intensity and percentage of cells
staining at each intensity. Intensities were classified from 0
(no staining) to 3 (very strong staining), whereas 10%
groupings were used for the percentage of cells that
stained positive. For each slide, a value designated as
HSCORE was obtained after the application of the follow-
ing algorithm: HSCORE = Σ (I + 1) × PC, where I and PC
represent the intensity and the percentage of cells that
stained at each intensity, respectively. The immunostained
sections were evaluated independently by two patholo-
gists without knowledge of patients’ clinical data at the
time of review. Reproducibility of the scoring method
between two observers was greater than 90%. The agree-
ment between the two observers is with respect to the
consideration of positive or negative tumors, not with
respect to the HSCORE values. In the remaining cases, in
which discrepancies had been noted, differences were
settled by consensus review of corresponding slides.
Statistical analysis
Analysis of differences in lysozyme values between two
groups of patients was performed with the Mann-Whitney
U test. Relationships between more than two groups were
evaluated by the Kruskal-Wallis test. Survival curves were
calculated using the Kaplan-Meier [23] method, and differ-
ences between curves were evaluated with the Log-rank
test [24]. Cox’s regression model [25] was also used to
examine several combinations and interactions of prog-
nostic factors in a multivariate analysis.
The following variables were included in the analysis: age,
tumor size, histological grade, nodal status, and estrogen
receptor status.
Selection of prognostic variables was performed with
Cox’s model using the stepwise regression option from
BMDP software [26]. Statistical significance was estab-
lished at the P < 0.05 level.
Results
The specificity of the antibody against human lysozyme
was tested by western blot. As can be seen in Fig. 1, the
antibody binds a protein with the same electrophoretic
mobility as lysozyme in human milk. Thus, the antibody
recognizes the lysozyme present in human milk, but does
not recognize lysozyme from different species (chicken),
nor any other protein present in a tumor cytosol or
human serum. This antibody recognizes complete
lysozyme, not part of it. Thus, the antibody cannot be
blocked by a peptide, and inhibition is only feasible using
complete human lysozyme, as shown in Fig. 1. The con-
centration of the blocking peptide that would be required
cannot be stated because it varies depending on the
human milk sample used. It should be measured as con-
centration per volume (mg/cm3), but the lysozyme we
analyzed was measured in solid phase (mg/cm2), and
they are not comparable.
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Immunohistochemical staining of MBCs was also done
using controls that involved preincubation, after
30 minutes, of the antibody with human milk. Fig. 2 shows
representative examples of these controls.
All 15 specimens from patients with gynecomastia
showed lysozyme-negative immunostaining. On the other
hand, we did not find normal ducts beside the tumors.
A total of 27 of 60 carcinomas (45%) stained positively for
lysozyme, with clear differences among them with regard
to intensity and percentage of staining cells. The mean
HSCORE value was 85.6.
Tumor characteristics (tumor size, nodal status, metastasis
status at the time of diagnosis, histological grade and type
and estrogen receptor status) are shown in Table 1. Distri-
bution of lysozyme HSCORE values is shown in Fig. 3. In
the group of 27 lysozyme-positive tumors, one tumor was
weakly stained (HSCORE<100), 14 were moderately
stained (100<HSCORE<200), and the remaining 12
tumors were strongly positive (HSCORE>200).
The wide variability of lysozyme values obtained sug-
gested a wide variability in biological and clinical behavior
of breast carcinomas and the potential value of lysozyme
expression as a prognostic marker.
Statistical analysis showed that lysozyme HSCORE values
in relation to age, tumor size, nodal status, histological
grade, estrogen receptor status, metastasis and histologi-
cal type did not increase the statistical significance
(Table 1). These facts prompted us to evaluate the poten-
tial role of lysozyme as an independent prognostic factor
in MBC.
The potential association between lysozyme immunostain-
ing and relapse-free survival (RFS) and overall survival was
Breast Cancer Research    Vol 4 No 6 Serra et al.
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Figure 1
Immunoblot analysis of the specificity of the antibody: the proteins of
several samples were separated by SDS-PAGE under reducing
conditions, and transferred to a filter. Then, the filter was incubated
with antibody against human lysozyme and developed. The proteins
recognized by the antibody appear as dark bands against a uniform
background. Molecular mass markers are indicated on the left of the
gel but not shown in the gel itself. lysoz. = lysozyme.
Figure 2
Photomicrographs corresponding to the immunostaining of the same male breast tumour (a) using antilysozyme (×100) and (b) using the same
dilution of the antibody previously incubated with human milk (×100).
(a)                                                                                                                  (b)
retrospectively evaluated in 57 male patients without
metastasis at the time of diagnosis. First, by statistical
analysis, we defined an optimal cut-off value of the ability
of lysozyme values to predict the RFS of the study popula-
tion (Fig. 4). Chi-squared analysis led us to define a
HSCORE of 100 as the optimal cut-off, with the ability to
identify 57.9% of patients as having low or negative
lysozyme values (Chi-squared = 5.04; P = 0.0248). Using
this cut-off value, relapse was confirmed in 3 of 33
patients (9.10%) with low-level or lysozyme-negative carci-
nomas, and in 8 of 24 (33.3%) with high-level or lysozyme-
positive tumors.
Differences between RFS curves for these two groups of
patients were significant at level P < 0.05 (Fig. 5). Simi-
larly, during the study period there was one death (3%)
because of recurrence in patients with lysozyme-low or
-negative tumors and three deaths (12.5%) in the group of
lysozyme-high or -positive tumors. Differences between
overall survival curves calculated for these two groups of
patients were not significant (Fig. 6).
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Table 1
Lysozyme HSCORE values classified according to various characteristics of patients and tumors
HSCORE*
Characteristics n Mean ± s.e Median (range) P
Total tumors 60 85.6 ± 13.6 0 (0–320)
Age n.s.
<60 15 85.3 ± 28.8 0 (0–270)
≥60 45 85.7 ± 15.6 0 (0–320)
Tumor size n.s.
T1 20 77.5 ± 22.7 0 (0–270)
T2 19 110 ± 27.3 100 (0–320)
T3–T4 21 71.4 ± 21.3 0 (0–270)
Nodal status n.s.
N0 32 89.6 ± 19.7 0 (0–320)
N+ 28 84.1 ± 19.5 0 (0–270)
Histological grade n.s.
I 12 62.5 ± 34 0 (0–320)
II 28 102.8 ± 20.1 110 (0–270)
III 20 75.5 ± 21.9 0 (0–270)
Metastasis status n.s.
M0 57 87.7 ± 14.2 0 (0–320)
M1 3 46.6 ± 46.6 0 (0–140)
Estrogen receptor status (fmol/mg protein) n.s.
≥10 30 81.6 ± 18.5 0 (0–270)
<10 3 0 0 (0)
Histological type n.s.
Ductal 53 93.5 ± 14.8 0 (0–320)
Lobular 2 0 0 (0)
Papillary 3 60 ± 60 0 (0–180)
Cribiform 2 0 0 (0)
*Semiquantitive immunostaining score for lysozyme. s.e. = standard error; n.s. = not significant.
Figure 3
Distribution of HSCORE values obtained by immunohistochemical
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Univariate analysis confirmed that both nodal involvement
(P < 0.005) and high lysozyme values (P < 0.05) were sig-
nificant predictors of short RFS (Table 2). In addition, mul-
tivariate analysis according to Cox’s regression model
showed that nodal status (P < 0.0005) and high lysozyme
levels (P < 0.05) were significant independent indicators
of RFS (Table 3).
Discussion
This is, at present, the first report showing the expression
and the prognostic role of lysozyme in MBCs, suggesting
that lysozyme could represent a new prognostic indicator
of unfavorable outcome in MBC.
The different behavior of lysozyme according to sex of
patients is remarkable. Whereas this protein has been
detected in 7% of fluid secretions from normal healthy
women [12], it is present in 15% of the normal epithelium
beside female breast tumors [14]. On the other hand,
lysozyme has not been detected in male patients with
gynecomastia. Moreover, we did not find normal ducts
beside the tumors. Thus, it was impossible to analyze the
Breast Cancer Research    Vol 4 No 6 Serra et al.
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Figure 6
Overall survival as a function of lysozyme values in 57 males with





























Determination of the cut-off value of lysozyme able to predict RFS in
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and tumor 5 years 10 years 
characteristics n (% ± s.e.) (% ± s.e.) P
Age n.s.
<60 16 100 66 ± 27
≥60 41 71 ± 8 71 ± 8
Tumor size n.s.
T1 20 76 ± 12 50 ± 2
T2 19 94 ± 5 94 ± 5
T3–T4 18 64 ± 13 –
Nodal status <0.005
N0 32 95 ± 4 95 ± 4
N+ 25 61 ± 11 41 ± 18
Histological grade n.s.
I 12 100 –
II 25 81 ± 8 81 ± 8
III 20 68 ± 12 41 ± 18
Lysozyme* <0.05
≥100 25 64 ± 11 64 ± 11
<100 84 93 ± 4 75 ± 17
*Semiquantitive immunostaining score. s.e. = standard error; n.s. = not
significant.
Figure 5
RFS as a function of lysozyme values in 57 males with breast cancer.






























potential immunostaining of lysozyme in normal male
breast ducts due to the fact that, in the normal male
breast, gland epithelium does not exist, or is atrophic. But
the most important difference shown in the present study
has been the opposite meaning of lysozyme secretion in
FBC and MBC.
Several biological aspects of lysozyme could contribute to
explain the apparent disadvantage conferred by the
expression of this protein in MBC and the different
meaning of lysozyme in FBC. Lysozyme has been
detected in normal female breast tissue and in benign
mammary lesions [12] as well as in a subset of female
breast tumors (69.4%), in which it has been associated
with factors of favorable outcome (histological grade,
nodal status, RFS, overall survival) [14]. This association
with histological grade may indicate that these female
breast tumors possess the required degree of differentia-
tion to synthesize the protein. Milk proteins are synthe-
sized by the mammary epithelium in response to a
complex hormonal release during pregnancy and lactation.
Although different steroid and peptide hormones cooper-
ate in this process, it is widely accepted that prolactin
plays a primary role by increasing transcription of milk
genes [27]. Thus, considering that it has been demon-
strated that breast cancer cells may show the ability to
synthesize a significant amount of biologically active pro-
lactin [28], we may speculate on a potential relationship
between lysozyme and prolactin. In addition, several
authors have described prolactin receptor expression in
about 50% of breast carcinomas [29–33], and shown that
receptor expression is more intense in the tumor tissue
than in the adjacent normal breast tissue [34].
It is worthwhile mentioning that the optimal cut-off value of
lysozyme able to predict RFS in MBC was 100, the same
value we established in our study on the role of lysozyme
in FBC [14]. Although the prognosis is different in MBC
and FBC, this could suggest that this level of lysozyme
has a biological value in breast cancer of both sexes.
It is difficult to find a plausible explanation for the different
prognostic meaning of lysozyme in MBC. The easiest
explanation could be related to the different hormonal
milieux. There are more estrogen-receptor-positive tumors
in patients with MBC than in FBC [1–6]. Moreover, the
higher expression in MBC of other hormonally induced
proteins, such as Bcl-2, Zn-α2-glycoprotein, apolipopro-
tein D, and pepsinogen C, is also well known [17,18].
Another explanation could be that, while the female breast
is normally prepared to produce lysozyme, the male breast
is not. Thus, its expression by a subset of MBCs may
reflect the important transformation undergone by these
tissues that results in them behaving as lysozyme-produc-
ing carcinomas. This, however, is in contrast with the
results of our study, which was unable to show any rela-
tionship between lysozyme HSCORE levels and histologi-
cal grade.
In conclusion, this study demonstrates that lysozyme, a
protein normally present in human milk, is expressed by
tumor tissue from a significant percentage of males with
breast cancer. Moreover, our results show a prognostic
significance of lysozyme in MBC with an opposite prog-
nostic meaning of lysozyme in FBC. These controversial
results can open new fields in the investigation of the hor-
monal regulation of breast cancer. Finally, further studies
are to be made in order to clarify the induction of lysozyme
by prolactin, opening new insights for other modalities of
hormonal treatment in breast cancer of both sexes.
Acknowledgements
The authors thank all members of the following participating clinical
centers in Spain (listed in alphabetical order): Hospital Virgen de los
Lirios de Alcoy, Hospital General de Alicante, Hospital Central de
Asturias, Hospital Nuestra Señora de Sonsoles de Ávila, Hospital San
Agustín de Avilés, Hospital Virgen de la Luz de Cuenca, Hospital de la
Marina Alta de Denia, Hospital General de Elche, Hospital de Elda,
Hospital de Jove de Gijón, Hospital de Cabueñes de Gijón, Fundación
Jiménez Díaz de Madrid, Hospital Ramón y Cajal de Madrid, Hospital
Clínico San Carlos de Madrid, Hospital de la Vega Baja de Orihuela,
Centro Médico de Oviedo, Hospital Dr. Peset de Valencia.
We also thank Professor Carlos López-Otín, Departamento de Bio-
química, Universidad de Oviedo, Asturias, Spain, for his interesting
comments.
References
1. Crichlow RW, Galt SW: Male breast cancer. Surg Clin North
Am 1990, 70:1165-1177.
2. Adami HL, Haulinen T, Ewetz M: The survival pattern in male
breast cancer: an analysis of 1429 patients from the Nordic
countries. Cancer 1989, 64:1177-1182.
3. Heller KS, Rosen PP, Schottenfeld D: Male breast cancer: a clin-
icopathologic study of 97 cases. Ann Surg 1978, 188:60-65.
4. Appelqvist P, Salmo M: Prognosis of carcinoma of the male
breast. Acta Chir Scand 1982, 148:499-502.
5. Ciatto S, Iossa A, Bonardi R: Male breast carcinoma: review of
a multicenter series of 150 cases. Tumori 1990, 76:555-558.
Available online http://breast-cancer-research.com/content/4/6/R16
Page 7 of 8
(page number not for citation purposes)
Table 3
Multivariate analysis of association of lysozyme with relapse-
free survival
Relapse-free survival (%)
Tumor Relative Regression 
characteristics risk coefficient ± s.e. P
Nodal status 2.90 ± 1.05 <0.0005
N0 0.30
N+ 5.50
Lysozyme* –1.37 ± 0.72 <0.05
<100 0.60
≥100 2.36
*Semiquantitive immunostaining score. s.e. = standard error.
6. Salvadori B, Saccozzi R, Manzari A, Andreola S, Conti RA,
Cusumano F, Grassi M: Prognosis of breast cancer in males:
an analysis of 170 cases. Eur J Cancer 1994, 30:930-935.
7. Fleming A: On a remarkable bacteriolitic element found in
tissues and secretions. Proc Roy Soc London 1922, B93:306-
317.
8. Petrakis NL: Physiologic, biochemical and cytologic aspects of
the nipple aspirate fluid. Breast Cancer Res Treat 1986, 8:7-19.
9. Biggar WD, Sturgess JM: Role of lysozyme in the microbicidal
activity of rat alveolar macrophages. Infection Immunol 1977,
16:974-982.
10. Klokars ML, Robers P: Stimulation of phagocytosis by human
lysozyme. Acta Haematol 1976, 52:289-295.
11. Sánchez LM, Vizoso F, Díez-Itza I, López-Otín C: Identification of
the major protein components in breast secretions from
women with benign and malignant breast diseases. Cancer
Res 1992,52:95-100.
12. Vizoso F, Sánchez LM, Díez-Itza I, Lamelas ML, López-Otín C:
Factors affecting protein composition of breast secretions
from nonlactating women. Breast Cancer Res Treat 1992, 23:
251-258.
13. Vizoso F, Díez-Itza I, Sánchez LM, Ruibal A, López-Otín C: Rela-
tionship between prolactin levels and composition of breast
secretions in nonlactating women. J Clin Endocinol Metab
1994, 79:525-529.
14. Vizoso F, Plaza E, Vázquez J, Serra C, Lamelas ML, González LO,
Merino AM, Méndez J: Lysozyme expression by breast carcino-
mas, correlation with clinicopathologic parameters, and prog-
nostic significance. Ann Surg Oncol 2001, 8:667-674.
15. Serra C, Vizoso F, Rodriguez JC, Merino AM, González LO, Bal-
tasar A, Pérez-Vázquez MT, Medrano J: Expression of pepsino-
gen C in gynecomastias and male breast carcinomas. World J
Surg 1999, 23:439-445.
16. Serra C, Vizoso F, Lamelas ML, Rodríguez JC, González LO, Bal-
tasar A, Medrano J: Expression and clinical significance of
apolipoprotein D in male breast cancer and gynaecomastia.
Br J Surg 1999, 86:1190-1197.
17. Serra C, Vizoso F, Lamelas ML, Rodríguez JC, González LO,
Merino AM, Baltasar A, Pérez-Vázquez MT, Medrano J: Compara-
tive study of two androgen-induced (Apolipoprotein D and
Pepsinogen C) prognostic markers between female and male
breast carcinoma. Int J Surg Invest 2000, 2:183-192.
18. Weber-Chappuis K, Bieri-Burger S, Hurliman J: Comparison of
prognostic markers detected by immunohistochemistry in
male and female breast carcinomas. Eur J Cancer 1996, 32:
1686-1692.
19. Bloom HJG, Richardson WW: Histological grading and prog-
nosis in breast cancer. Br J Cancer 1957, 11:359-377.
20. Vaitukaitis JL: Production of antisera with small doses of
immunogen: multiple intradermal injections. Methods Enzymol
1981, 73:46-52.
21. Laemmili UK: Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature 1970, 227:
680-685.
22. McCarty KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L,
Konrath J, Soper JT, Budwit DA, Creasman WT: Use of a mono-
clonal anti-estrogen receptor antibody in the inmunohisto-
chemical evaluation of human tumors. Cancer Res 1986,
46:4244-4248.
23. Kaplan EL, Meier P: Nonparametric estimation from incom-
plete observations. J Am Stat Assoc 1958, 53:457-481.
24. Mantel M, Myers M: Problems of convergence of maximum
likelihood iterative procedures in muliparameter situations. J
Am Stat Assoc 1971, 66:484-491.
25. Cox DR: Regression models and life tables. J R Stat Soc B
1972, 34:187-220.
26. Dixon WJ, Brown MB, Engelman L, Frane JW, Hill MA, Jennrich
RI: BMDP statistical software. Berkeley: University of California
Press; 1985.
27. Topper YJ, Freeman CS: Multiple hormone interactions in the
developmental biology of the mammary gland. Physiol Rev
1989, 60:1049-1106.
28. Ginsburg E, Vonderhaar BK: Prolactin synthesis and secretion
by human breast cancer cells. Cancer Res 1995, 55:2591-
2595.
29. Holdaway MI, Friesen HG: Hormone binding by human
mammary carcinoma. Cancer Res 1977, 37:1946-1952.
30. Partridge RK, Hahnel R: Prolactin receptors in human breast
carcinoma. Cancer 1979, 43:643-646.
31. Turcot Lemay L, Kelly PA: Prolactin in human breast tumors. 
J Natl Cancer Inst 1982, 68:381-383.
32. Bonneterre J, Peurat JP, Vandewalle B, BeuscartT R, Vie MC,
Cappelaere P: Prolactin receptors in human breast cancer. Eur
J Cancer 1982, 18:1157-1162.
33. Touraine F, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C,
Nicolas A, Triven C, Postel-Vinay MC, Kutten F, Kelly PA:
Increased expression of prolactin receptor gene assessed by
quantitative polymerase chain reaction in human breast
tumors versus normal breast tissues. J Clin Endocrinol Met
1998, 83:667-674.
34. Peyrat JP, Djiane J, Bonneterre J, Vandewalle B, Vennini PH, Delo-
belle A, Depadt G, Lefebvre J: Stimulation of DNA syntesis by
prolactin in human breast tumor explants. Relation to pro-
lactin receptors. Anticancer Res 1984, 4:257-262.
Breast Cancer Research    Vol 4 No 6 Serra et al.
Page 8 of 8
(page number not for citation purposes)
